The Transferrin Receptor-Directed CAR for the Therapy of Hematologic Malignancies

The Transferrin Receptor-Directed CAR for the Therapy of Hematologic Malignancies

As many patients ultimately relapse after chimeric antigen receptor (CAR) T-cell therapy, identification of alternative targets is currently being evaluated. Substantial research efforts are underway to develop new targets. The transferrin receptor (TfR) is prevalently expressed on rapidly prolifera...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak: Zilong Guo, Yirui Zhang, Mingpeng Fu, Liang Zhao, Zhen Wang, Zhuoshuo Xu, Huifen Zhu, Xiaoli Lan, Guanxin Shen, Yong He, Ping Lei
Formatua: Artikulua
Hizkuntza:English
Argitaratua: Frontiers Media S.A. 2021-03-01
Saila:Frontiers in Immunology
Gaiak:
transferrin receptor
chimeric antigen receptor
alternative target
hematological malignancies
T-cell acute lymphoblastic leukemia
Sarrera elektronikoa:https://www.frontiersin.org/articles/10.3389/fimmu.2021.652924/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.652924/full

Antzeko izenburuak